Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

Benzer Materyaller

• DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
  Yazar:: Li, Yang‐ling, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  Yazar:: Nishino, Mizuki, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
  Yazar:: Zou, Bin, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
  Yazar:: Paola Ulivi, ve diğerleri
  Baskı/Yayın Bilgisi: (2014-12-01)
• Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
  Yazar:: Ulivi, Paola, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)